# Sumanta K. Pal

Source: https://onco.cc/people/sumanta-pal/  
OnCo record `sumanta-pal` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led SWOG 1500, the first randomised trial to set a standard for papillary kidney cancer, and studies of the microbiome in RCC immunotherapy.

## Summary

Sumanta Pal was principal investigator of SWOG PAPMET (S1500), which showed cabozantinib outperforms sunitinib in metastatic papillary renal cell carcinoma, the first practice-changing randomised trial in a non-clear-cell histology, and a lead investigator of COSMIC-313 and CONTACT-03. He led the randomised trial of the live bacterial product CBM588 with immunotherapy. He co-directs the kidney cancer programme at City of Hope.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: rcc; swog; microbiome
- Role: Professor and Co-Director, Kidney Cancer Program, City of Hope
- Specialisms: Renal cell carcinoma; Non-clear-cell histologies; Microbiome and immunotherapy; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Pal%20SK%5BAuthor%5D%20renal%20cell

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [City of Hope](https://onco.cc/institutions/city-of-hope/)
- trials: [CONTACT-03](https://onco.cc/trials/contact-03/), [COSMIC-313](https://onco.cc/trials/cosmic-313/), [PAPMET (SWOG S1500)](https://onco.cc/trials/papmet/)

---
JSON: https://onco.cc/api/v1/entities/sumanta-pal.json